rosiglitazone has been researched along with bexarotene in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 6 (40.00) | 29.6817 |
| 2010's | 6 (40.00) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Abad, MC; Askari, HB; De, D; Gaul, MD; Geisler, JG; Kasturi, J; Kemmerer, M; Kim, AJ; Lenhard, JM; Lin, L; Liu, J; O'Neill, JC; Patch, RJ; Player, MR; Rentzeperis, D; Searle, LL; Zhu, X | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Gellrich, L; Heering, J; Kaiser, A; Kalinowsky, L; Kilu, W; Merk, D; Ohrndorf, J; Pollinger, J; Proschak, E; Schierle, S; Schmidt, J | 1 |
| Chaikuad, A; Gellrich, L; Heitel, P; Kaiser, A; Knapp, S; Merk, D; Ohrndorf, J; Pollinger, J; Schierle, S | 1 |
| Fujihara, M; Ito, S; Kakuta, H; Kawasaki, M; Makishima, M; Motoyama, T; Nakano, S; Takamura, Y; Watanabe, M; Yamada, S | 1 |
| Bischoff, ED; Boehm, MF; Cesario, RM; Crombie, DL; Davies, PJ; Hamann, LG; Heyman, RA; Jow, L; Mondon, CE; Mukherjee, R; Nadzan, AM; Paterniti, JR | 1 |
| Blanchard, SG; Furfine, ES; Ittoop, O; Jain, RG; Lenhard, JM; Orband-Miller, LA; Paulik, MA; Weiel, JE | 1 |
| Bissonnette, RP; Cesario, RM; Lamph, WW; Stone, J; Yen, WC | 1 |
| Mohler, DL; Shen, G | 1 |
| Greer, JP; Koyama, T; Sepmeyer, JA; Zic, JA | 1 |
| Baggstrom, MQ; Fracasso, PM; Govindan, R; Read, WL | 1 |
| Berenz, A; Haugen, BR; Hays, WR; Klopper, JP; Loi, M; Pugazhenthi, U; Said, S; Sharma, V | 1 |
| Amagaya, S; Inoue, M; Kotani, H; Mizukami, H; Tanabe, H | 1 |
| Chen, JY; Chi, CW; Hsu, YC; Lee, CH; Lee, HC; Wang, JJ | 1 |
1 review(s) available for rosiglitazone and bexarotene
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for rosiglitazone and bexarotene
| Article | Year |
|---|---|
Open-label pilot study of combination therapy with rosiglitazone and bexarotene in the treatment of cutaneous T-cell lymphoma.
Topics: Aged; Anticarcinogenic Agents; Bexarotene; Biopsy, Needle; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Immunohistochemistry; Lymphoma, T-Cell, Cutaneous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pilot Projects; Risk Assessment; Rosiglitazone; Single-Blind Method; Survival Analysis; Tetrahydronaphthalenes; Thiazolidinediones; Treatment Outcome | 2007 |
A phase I study of bexarotene and rosiglitazone in patients with refractory cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Female; Humans; Male; Middle Aged; Neoplasms; Rosiglitazone; Tetrahydronaphthalenes; Thiazolidinediones | 2008 |
12 other study(ies) available for rosiglitazone and bexarotene
| Article | Year |
|---|---|
Identification of diaryl ether-based ligands for estrogen-related receptor α as potential antidiabetic agents.
Topics: Administration, Oral; Animals; Binding, Competitive; Biological Availability; Crystallography, X-Ray; Diabetes Mellitus; Dogs; ERRalpha Estrogen-Related Receptor; Ethers; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Ligands; Macaca fascicularis; Male; Mice; Mice, Knockout; Models, Molecular; Molecular Structure; Obesity; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Structure-Activity Relationship; Thiazolidinediones; Triglycerides | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Tuning Nuclear Receptor Selectivity of Wy14,643 towards Selective Retinoid X Receptor Modulation.
Topics: Animals; HEK293 Cells; Hep G2 Cells; Humans; Male; Mice, Inbred C57BL; Microsomes, Liver; Molecular Structure; Peroxisome Proliferator-Activated Receptors; Pyrimidines; Rats; Retinoid X Receptors; Structure-Activity Relationship | 2019 |
A Novel Biphenyl-based Chemotype of Retinoid X Receptor Ligands Enables Subtype and Heterodimer Preferences.
Topics: | 2019 |
Discovery of a "Gatekeeper" Antagonist that Blocks Entry Pathway to Retinoid X Receptors (RXRs) without Allosteric Ligand Inhibition in Permissive RXR Heterodimers.
Topics: Allosteric Regulation; Circular Dichroism; Crystallography, X-Ray; Dimerization; Ligands; Retinoid X Receptors | 2021 |
Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists.
Topics: Animals; Bexarotene; Blood Glucose; Cells, Cultured; Diabetes Mellitus, Type 2; Female; Glucose Tolerance Test; Hypoglycemic Agents; Insulin; Insulin Resistance; Ligands; Mice; Mice, Inbred C57BL; Mice, Obese; Nicotinic Acids; Obesity; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Rosiglitazone; Tetrahydronaphthalenes; Thiazoles; Thiazolidinediones; Transcription Factors; Transfection | 1997 |
HIV protease inhibitors block adipogenesis and increase lipolysis in vitro.
Topics: Adipocytes; Animals; Azo Compounds; Bexarotene; Carbamates; Carrier Proteins; Cell Differentiation; Cells, Cultured; Coloring Agents; Fatty Acid-Binding Proteins; Furans; HIV Protease Inhibitors; Indinavir; Insulin; Lipolysis; Lipoprotein Lipase; Nelfinavir; Neoplasm Proteins; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Ritonavir; RNA, Messenger; Rosiglitazone; Saquinavir; Stem Cells; Sulfonamides; Tetrahydronaphthalenes; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides | 2000 |
Differentiation and growth inhibition mediated via the RXR:PPARgamma heterodimer in colon cancer.
Topics: Animals; Anticarcinogenic Agents; Bexarotene; Cell Differentiation; Cell Proliferation; Colonic Neoplasms; Cyclooxygenase 2; Fibrinolytic Agents; Humans; Male; Membrane Proteins; Mice; Mice, Nude; PPAR gamma; Prostaglandin D2; Retinoid X Receptors; Rosiglitazone; Tetrahydronaphthalenes; Thiazolidinediones; Transplantation, Heterologous; Tumor Cells, Cultured | 2006 |
The synthesis of tethered ligand dimers for PPARgamma-RXR protein heterodimers.
Topics: Bexarotene; Dimerization; Ligands; PPAR gamma; Retinoid X Receptors; Rosiglitazone; Tetrahydronaphthalenes; Thiazolidinediones | 2006 |
Retinoid and thiazolidinedione therapies in melanoma: an analysis of differential response based on nuclear hormone receptor expression.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Bexarotene; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Ligands; Melanoma; Mice; PPAR gamma; Receptors, Cytoplasmic and Nuclear; Retinoid X Receptors; Retinoids; RNA, Small Interfering; Rosiglitazone; Tetrahydronaphthalenes; Thiazolidinediones; Xenograft Model Antitumor Assays | 2009 |
A naturally occurring rexinoid, honokiol, can serve as a regulator of various retinoid x receptor heterodimers.
Topics: 3T3-L1 Cells; Animals; Anticarcinogenic Agents; Bexarotene; Biphenyl Compounds; Caco-2 Cells; Dimerization; Humans; Lignans; Liver X Receptors; Magnolia; Mice; Orphan Nuclear Receptors; Plant Extracts; PPAR gamma; Receptors, Calcitriol; Receptors, Cytoplasmic and Nuclear; Retinoid X Receptors; RNA, Messenger; Rosiglitazone; Signal Transduction; Tetrahydronaphthalenes; Thiazolidinediones | 2012 |
Combination of peroxisome proliferator-activated receptor gamma and retinoid X receptor agonists induces sodium/iodide symporter expression and inhibits cell growth of human thyroid cancer cells.
Topics: Bexarotene; Cell Line, Tumor; Cell Proliferation; Drug Therapy, Combination; Epithelial-Mesenchymal Transition; Humans; PPAR gamma; Retinoid X Receptors; Rosiglitazone; Symporters; Thyroid Neoplasms; Tumor Hypoxia | 2020 |